Chimerix

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chimerix transitions successfully, eyes oncology pipeline growth

Chimerix navigated a key transition in 2022, focusing on oncology pipeline
Financially, the company aims to fund operations into 2027
Promising clinical data on ONC201 and ONC206 highlight potential market opportunities

Chimerix reports operational and financial progress, poised for oncology growth

Chimerix demonstrated operational and financial progress in Q1 2023, with a strong focus on advancing its oncology pipeline and addressing analyst inquiries.
The company's innovative research capabilities, promising drug candidates, and solid financial position position it well for future growth and success.

Chimerix reports robust Q2 performance and strategic leadership recruitment

Chimerix's strong performance in global engagement and dose escalation studies positions them well for future growth in targeted oncology.
Maintaining financial discipline and leadership recruitment indicate a strategic approach to capital allocation and pipeline expansion.
Clear evaluation criteria and data sharing timelines will be crucial for addressing challenges and seizing opportunities in advancing their programs.

Chimerix (CMRX) advances oncology studies, poised for commercialization success

Chimerix (CMRX) showcased progress in ONC201 and ONC206 studies, with a focus on scientific validation and commercialization readiness.
Financially stable with a cash balance of $217 million, the company is well-positioned for future growth and operational sustainability.
Engagement with the medical community and strategic planning for market entry highlight Chimerix's commitment to innovation and patient care.

Chimerix reports disciplined finances, positive trial results, eyes global expansion

Chimerix showcased financial discipline amidst a net loss, while emphasizing positive Phase II results of ONC201. The company is focused on advancing the Phase III ACTION study with global enrollment and strategic management appointments. Challenges include timely execution of the study and managing enrollment trends, with opportunities in commercialization and partnerships.

Chimerix reports robust Q1 earnings, eyes global drug approvals

Chimerix's Q1 2024 earnings call highlighted strong financials, progress in key studies, and strategic growth initiatives. While facing challenges in enrollment, regulatory pathways, and commercialization, the company remains optimistic about its pipeline and financial discipline.

Chimerix advances key studies, maintains strong finances amid challenges

Chimerix (CMRX) demonstrated progress in key clinical studies and maintained a strong financial position in Q2 2024.
While facing challenges with increased R&D expenses and a net loss, the company is strategically investing in growth opportunities.
Opportunities lie in potential drug registrations, intensified dosing schedules, and investments in launch readiness for future success.
Overall, Chimerix remains focused on advancing its pipeline and financial strategy to drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Chimerix, Inc. (NASDAQ:CMRX ) Q3 2024 Earnings Call November 7, 2024 8:30 AM ET Company Participants Will O'Connor - Investor Relations Mike Andriole - President and Chief Executive Officer Josh Allen - Chief Scientific Officer Michelle LaSpaluto - Chief Financial Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Operator Good morning, ladies and gentlemen and welcome to the Chimerix Third Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today's call, Will O'Connor from Stern Investor Relations.

Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript

Chimerix (CMRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago.

Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates

DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview.

Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 130,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Chimerix, Inc. (NASDAQ:CMRX ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Mike Andriole - President and Chief Executive Officer Michelle LaSpaluto - Chief Financial Officer Josh Allen - Chief Technology Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Soumit Roy - Jones Research Ed White - HC Wainwright Troy Langford - TD Cowen Operator Good morning, ladies and gentlemen. And welcome to the Chimerix Second Quarter 2024 Earnings Conference Call.

Chimerix, Inc. (CMRX) Q2 2024 Earnings Call Transcript

Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago.

Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates

DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Chimerix, Inc. (NASDAQ:CMRX ) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Will O'Connor – Stern Investor Relations Mike Andriole – President and Chief Executive Officer Allen Melemed – Chief Medical Officer Josh Allen – Chief Technology Officer Michelle LaSpaluto – Chief Financial Officer Tom Riga – Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft – Jefferies Naureen Quibria – Capital One Soumit Roy – Jones Research Troy Langford – TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix First Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today's call, Will O'Connor of Stern Investor Relations.

Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript

– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 –

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview.

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

Chimerix, Inc. is a biotech company focused on developing novel treatments for high-grade glioma and other therapies. Their main clinical asset, doraviprone, has shown promising results in treating H3 K27M-mutated diffuse midline glioma. The company has a strong financial position with over $200 million in assets and a runway of 2+ years, making it an attractive investment for those with a longer-term outlook.

Chimerix: Tackling A Strong Unmet Need With Promising Data

Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript

– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 –

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, February 29, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2023, and to provide a business overview.

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience

Chimerix Appoints Lisa Decker to Board of Directors

DURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective December 1, 2023.

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 –

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 2, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business overview.

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite expected $200 million in liquidity by the end of 2023.

Chimerix: Dangerous Road, Thesis Intact

Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Chimerix, Inc. (NASDAQ:CMRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Michelle Laspaluto - Vice President of Strategic Planning and Investor Relations Mike Andriole - President and CEO Josh Allen - Chief Technology Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Joel Beatty - Baird Ed White - H.C. Wainwright Soumit Troy - Jones Trading Joseph Thome - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Second Quarter 2023 Earnings Conference Call.

Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript

– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 –

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Aptevo Therapeutics

Flexible Solutions

Glory Star New Media Group Holdings Ltd

Optex Systems Holdings Inc

X Financial - ADR

Yirendai Ltd. Sponsored

Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poor.

News for Chimerix Stock (CMRX)